T-细胞幼淋巴细胞白血病治疗的研究进展  

Research progress on the therapy of T-cell prolymphocytic leukemia

作　　者：杜云云[1] 李庆敏 

机构地区：[1]云南省第一人民医院血液科,昆明市650000 [2]云南省第一人民医院内分泌科,昆明市650000

出　　处：《中国肿瘤临床》2017年第21期1108-1111,共4页Chinese Journal of Clinical Oncology

摘　　要：幼淋巴细胞白血病(prolymphocytic leukemia,PLL)是一种罕见但恶性程度极高的成熟淋巴肿瘤,其中T-细胞幼淋巴细胞白血病(T-cell prolymphocytic leukemia,T-PLL)这种亚型被认为难以治愈,临床治疗目的主要是提高治疗有效率和延长缓解期。随着对白血病发生发展机制研究的不断深入,目前T-PLL的治疗手段取得了较大的进步,其中表观遗传学的干预治疗为治愈TPLL提供了新的研究方向,本文就T-PLL的治疗研究进展进行综述。Prolymphocytic leukemia is a rare disease with typical characteristics, including aggressive progression and high mortality rate, and T-cell prolymphocytic leukemia（T-PLL） is regarded as an intractable subtype. Current therapeutic approaches mainly aim to improve their efficacy and remission against this disease. This paper presents a review about the research progress on T-PLL therapies.With remarkable research progress on leukemia pathogenesis, therapies for T-PLL have been greatly enhanced. Among treatment strategies, epigenetic therapy shows potential for clinical applications.

关 键 词：T-细胞幼淋巴细胞白血病 表观遗传学 治疗 阿仑单抗 干细胞移植 

分 类 号：R733.7[医药卫生—肿瘤]